Progression in Cutaneous Malignant Melanoma Is Associated with Distinct Expression Profiles: A Tissue Microarray-Based Study

American Journal of Pathology

Volumn 164, Issue 1, 2004, Pages 193-203

  Alonso, Soledad R ^a   Ortiz, Pablo ^b   Pollán, Marina ^c   Pérez Gómez, Beatriz ^c   Sánchez, Lydia ^a   Acuña, Ma Jesús ^a   Pajares, Raquel ^a   Martínez Tello, Francisco J ^b   Hortelano, Carlos M ^d   Piris, Miguel A ^a   Rodríguez Peralto, José L ^b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c CARLOS III INSTITUTE OF HEALTH   (Spain)

^d MDS Pharma Services   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DNA; KI 67 ANTIGEN; MELANOMA ANTIGEN; PROTEIN BCL 6; PROTEIN P16; PROTEIN P16INK4A; PROTEIN P21; PROTEIN P27; TRANSCRIPTION FACTOR; TUMOR MARKER; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DISEASE ACTIVITY; DNA MICROARRAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; MISMATCH REPAIR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; VALIDATION PROCESS; ADULT; AGED; COMPARATIVE STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION PROFILING; GENETICS; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; REGRESSION ANALYSIS; SKIN TUMOR; THEORETICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; MODELS, THEORETICAL; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 1542574206     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)63110-0     Document Type: Article

References (42)

1. Urist MM, Karnell LH: The National Cancer Data Base: report on melanoma. Cancer 1994, 74:782-788
2. Sober AJ, Lew RA, Koh HK, Barnhill RL: Epidemiology of cutaneous melanoma: an update. Dermatol Clin 1991, 9:617-629
3. Koh HK: Cutaneous melanoma. N Engl J Med 1991, 325:171-182
4. Geller AC, Miller DR, Annas GD, Demierre MF, Gilchrest BA, Koh HK: Melanoma incidence and mortality among US whites, 1969-1999. JAMA 2002, 288:1719-1720
5. Crowson AN, Margo CM, Mihn MC: The melanocytic proliferations. A Comprehensive Textbook of Pigmented Lesions. New York, Wiley-Liss, 2001, pp 315-332, 501-513
6. Maelandsmo GM, Florenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Borresen AL, Fodstad O: Involvement of the pRb/p16/cdk4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas. Br J Cancer 1996, 73:909-916
7. Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R: Levels of cyclin D1 and D3 in malignant melanoma: deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 2000, 6:3614-3620
8. Soufir N, Avril MF, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, Benard J, Bressac-de Paillerets B: Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France: The French Familial Melanoma Study Group. Hum Mol Genet 1998, 7:209-216
9. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M, Pinkel D, Herlyn M, Bastian BC: Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res 2002, 62:3200-3206
10. Straume O, Sviland L, Akslen LA: Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000, 6:1845-1853
11. Grossman D, McNiff JM, Li F, Altieri DC: Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol 1999, 113:1076-1081
12. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4:844-847
13. Nocito A, Kononen J, Kallioniemi OP, Sauter G: Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001, 94:1-5
14. Garcia JF, Camacho FI, Morente M, Fraga M, Montalban C, Bellas TA, Castano A, Diez A, Flores T, Martin C, Martinez MA, Mazorra F, Menarguez J, Mestre MJ, Mollejo M, Saez AI, Sanchez L, Piris MA: Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003, 101:681-689
15. Breslow A: Thickness, cross-sectional areas, and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970, 172:902-908
16. Clark Jr WH, Elder DE, Guerry Dt, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC: Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989, 81:1893-1904
17. Benjamini Y, Hochberg Y: Controlling the false discovery rate and practical and powerful approach to multiple testing. J R Stat Soc 1995, B57:289-300
18. Natkunam Y, Warnke RA, Montgomery K, Falini B, van De Rijn M: Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001, 14:686-694
19. Kielhorn E, Provost E, Olsen D, D'Aquila TG, Smith BL, Camp RL, Rimm DL: Tissue microarray-based analysis shows phospho-β-catenin expression in malignant melanoma is associated with poor outcome. Int J Cancer 2003, 103:652-656
20. Polsky D, Bastian BC, Hazan C, Melzer K, Pack J, Houghton A, Busam K, Cordon-Cardo C, Osman I: HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res 2001, 61:7642-7646
21. Malumbres M, Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001, 1:222-231
22. Sauroja I, Smeds J, Vlaykova T, Kumar R, Talve L, Hahka-Kemppinen M, Punnonen K, Jansen CT, Hemminki K, Pyrhonen S: Analysis of G(1)/S checkpoint regulators in metastatic melanoma. Genes Chromosomes Cancer 2000, 28:404-414
23. Sparrow LE, Eldon MJ, English DR, Heenan PJ: p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998, 20:255-261
24. Florenes VA, Maelandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R: Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. Am J Pathol 1998, 153:305-312
25. Tang L, Li G, Tron VA, Trotter MJ, Ho VC: Expression of cell cycle regulators in human cutaneous malignant melanoma. Melanoma Res 1999, 9:148-154
26. Sviderskaya EV, Hill SP, Evans-Whipp TJ, Chin L, Orlow SJ, Easty DJ, Cheong SC, Beach D, DePinho RA, Bennett DC: p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst 2002, 94:446-454
27. Sotillo R, Garcia JF, Ortega S, Martin J, Dubus P, Barbacid M, Malumbres M: Invasive melanoma in Cdk4-targeted mice. Proc Natl Acad Sci USA 2001, 98:13312-13317
28. Yang FC, Merlino G, Chin L: Genetic dissection of melanoma pathways in the mouse. Semin Cancer Biol 2001, 11:261-268
29. Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L: Dual inactivation of RB and p53 pathways in RAS-induced melanomas. Mol Cell Biol 2001, 21:2144-2153
30. Tietze MK, Chin L: Murine models of malignant melanoma. Mol Med Today 2000, 6:408-410
31. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC: Germline mutations in the p161NK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996, 12:97-99
32. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D: A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 1995, 269:1281-1284
33. Walker GJ, Flores JF, Glendening JM, Lin AH, Markl ID, Fountain JW: Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes Chromosomes Cancer 1998, 22:157-163
34. Sanchez-Beato M, Camacho FI, Martinez-Montero JC, Saez AI, Villuendas R, Sanchez-Verde L, Garcia JF, Piris MA: Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression: p27/KIP1-cyclin D3 colocalization in tumor cells. Blood 1999, 94:765-772
35. Henriet P, Zhong ZD, Brooks PC, Weinberg KI, DeClerck YA: Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci USA 2000, 97:10026-10031
36. Chiodino C, Cesinaro AM, Ottani D, Fantini F, Giannetti A, Trentini GP, Pincelli C: Communication: expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol 1999, 113:415-418
37. Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW: Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001, 409:207-211
38. Okamoto T, Schlegel A, Scherer PE, Lisanti MP: Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 1998, 273:5419-5422
39. Liu J, Lee P, Galbiati F, Kitsis RN, Lisanti MP: Caveolin-1 expression sensitizes fibroblastic and epithelial cells to apoptotic stimulation. Am J Physiol 2001, 280:C823-C835
40. Liu J, Razani B, Tang S, Terman BI, Ware JA, Lisanti MP: Angiogenesis activators and inhibitors differentially regulate caveolin-1 expression and caveolae formation in vascular endothelial cells: angiogenesis inhibitors block vascular endothelial growth factor-induced down-regulation of caveolin-1. J Biol Chem 1999, 274:15781-15785
41. Engelman JA, Wykoff CC, Yasuhara S, Song KS, Okamoto T, Lisanti MP: Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem 1997, 272:16374-16381
42. Koleske AJ, Baltimore D, Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995, 92:1381-1385